Упрощенная HTML-версия
173
282. Oken M.M. Management of myeloma: Current and future approaches /
M.M. Oken // Cancer Control. – 1998. – Vol. 5, № 3. – P. 218-225.
283. Oken M.M. Standard treatment of MM / M.M. Oken // Mayo Clin. Proc. –
1994. – Vol. 69, № 8. – P. 781-786.
284. Olson H.M. Subacute cardiotoxicity of adriamycin in the rat: biochemical
and ultrastructural investigations / H.M. Olson, C. C. Capen // Lab. Invest. – 1977. –
Vol. 37, № 4. – P. 386-394.
285. Partsch H. Investigations on the pathogenesis of venous leg ulcers / H. Partsch // Acta
Chir. Scand. Suppl. – 1988. –Vol. 544. – P. 25-29.
286. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory
hematologic malignancies / R.Z. Orlowski [et al.] // J. Clin. Oncol. – 2002. – Vol. 20,
№ 22. – P. 4422-4427.
287. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin
in patients with advanced gastric carcinoma / Y.T. Jeen [et al.] // Cancer. – 2001. –
Vol. 91, № 12. – P. 2288-2293.
288. Prevention of dexamethasone-induced lymphocytic apoptosis in the
intestine and in Peyer patches by enteral nutrition / S. Ruiz-Santana [et al.] // JPEN J.
Parenter. Enteral Nutr. – 2001. – Vol. 25, № 6. – P. 338-345.
289. Prospective randomized trial comparing mitomycin, cisplatin, and
protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and
PVI 5-FU in advanced esophagogastric cancer / P. Ross [et al.] // J. Clin. Oncol. –
2002. – Vol.20, № 8. – P. 1996-2004.
290. Proteasome inhibitors: a novel class of potent and effective antitumor agents
/ Adams [et al.] // Cancer Res. – 1999. – Vol. 59, № 11. – P. 2615-2622.
291. Pushin la R.W. A study of glucocorticosteroid-induced pyknosis in the
thymus and lymph node of the adrenalectomized rat / R. W. la Pushin, E. de Harven
// J. Cell Biol. – 1971. – Vol. 50, № 3. – P. 583-597.
292. Pyogenic spondylitis by methicillinresistant Staphylococcus aureus
(MRSA) during M-VAC therapy: a case report / S. Danno [et al.] // Hinyokika Kiyo.
– 2005. – Vol. 51, № 6. – P. 389-392.